Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ISAL 2019 | European LeukemiaNet 2017 AML recommendations: impact on risk stratification and survival

Klaus Metzeler • 1 Mar 2019
ISAL 2019
Acute Myeloid Leukemia Leukemia

Klaus Metzeler, MD, of LMU Hospital Munich, Munich, Germany, discusses what changes came about from the 2017 European LeukemiaNet (ELN) recommendations for diagnosis and management of acute myeloid leukemia (AML) in adults. This interview was recorded at the International Symposium on Acute Leukemias (ISAL) 2019, held in Munich, Germany.

More from Klaus Metzeler

4:25
The challenges with accurately diagnosing and risk-stratifying patients with MDS
Klaus Metzeler • 16 Apr 2024
3:10
The role of NGS in MDS diagnosis
Klaus Metzeler • 16 Apr 2024
3:17
Pre-MDS states: novel therapeutic approaches, and determining appropriate trial endpoints
Klaus Metzeler • 5 May 2023
3:01
Challenges in distinguishing between pre-MDS states and MDS, and approaches to improve diagnosis
Klaus Metzeler • 5 May 2023

Related Videos

1:40
The role of CPX-351 in the AML treatment landscape & insights into the AMLSG 30-18 trial
Felicitas Thol • 19 Apr 2024
3:21
Integrating genomics and MRD in transplant decision-making for patients with AML
Jurjen Versluis • 22 Apr 2024
4:19
Blinatumomab to achieve remission and consolidation with haploSCT for pediatric ALL
Alberto Olaya-Vargas • 15 Apr 2024
3:32
Improving CAR-T therapy for ALL & lymphoma: allogeneic products & reducing CRS/ICANS
Sridhar Chaganti • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals